Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1534 • ACR Convergence 2020
Combined Thermal and Ultrasound Imaging in Rheumatoid Arthritis Is Superior to Either Imaging Alone in Terms of Correlation with the 28-joint Disease Activity Score
York Kiat Tan¹, Cassandra Hong¹, HuiHua Li², John Allen Jr³ and Julian Thumboo¹, ¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ²Health Services Research Unit, Singapore General Hospital, Singapore, Singapore, Singapore, ³Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore, Singapore
Background/Purpose: Combined thermal and ultrasound (US) imaging modalities in detecting joint inflammation in rheumatoid arthritis (RA) has not been evaluated relative to thermal or US…
Abstract Number: 1597 • ACR Convergence 2020
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Taylor Nelson¹, Gary Kunkel² and Grant Cannon², ¹University of Utah, Salt Lake City, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City
Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …
Abstract Number: 1720 • ACR Convergence 2020
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Hyoun-Ah Kim¹, Ryan Peterson², Gary Firestein³, David Boyle⁴, Jane Buckner⁵, Sylvia Posso⁶, Eddie James⁵, William Robinson⁷, Jaron Arbet², LauraKay Moss⁸, Roger Gilmore⁸, Lindsay Hartje⁸, Saman Barzideh⁸, Jennifer Seifert⁹, Navin Rao¹⁰, Frédéric Baribaud¹¹, Sunil Nagpal¹², Alyssa Johnson¹³, V Michael Holers¹⁴ and Kevin D. Deane¹⁵, ¹University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, ²Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, ³University of California, San Diego, La Jolla, CA, ⁴UC San Diego, San Diego, CA, ⁵Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Stanford University, Palo Alto, CA, ⁸University of Colorado Anschutz Medical Campus, Aurora, CO, ⁹Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Janssen Reserach and Development, Spring House, PA, ¹³Janssen Research and Development, Spring House, PA, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ¹⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
Abstract Number: 1736 • ACR Convergence 2020
Health Assessment Questionnaire Predicts All-Cause Mortality at One Year in Patients with Early Rheumatoid Arthritis
Safoora Fatima¹, Orit Schieir², Marie-France Valois³, Susan Bartlett³, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward C Keystone⁸, Diane Tin⁹, Carter Thorne⁹, Vivian Bykerk¹⁰, Janet Pope¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹University of Western Ontario, London, ON, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹²Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Patients with RA are at greater risk of mortality than the general population. Higher HAQ disability has been associated with hospitalizations and mortality in…
Abstract Number: 1754 • ACR Convergence 2020
The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study
Elena Myasoedova¹, John Davis¹, Vanessa Kronzer¹, Rachel Giblon¹, Elizabeth Atkinson¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA), many patients do not achieve remission or full physical functioning. We have previously shown that…
Abstract Number: 1785 • ACR Convergence 2020
Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
Jazzia Emily Diaz-Angulo¹, Cassandra M. Skinner-Taylor¹, Lorena Perez-Barbosa¹, Eugenio Salvador Barriga-Maldonado¹, Marco Valdovinos², Rita Pineda-Sic¹, Jesus Alberto Cardenas-de la Garza¹, Gabriel Figueroa-Parra³, Janett Carmen Riega-Torres⁴ and Dionicio Ángel Galarza-Delgado⁵, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey, Nuevo Leon, Mexico, ²Hospital Universitario José Eleuterio González, Monterrey, Nuevo Leon, Mexico, ³Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey NL, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The importance of safe and effective contraception for women with rheumatic diseases has been increasing. Several studies have demonstrated that carefully planned pregnancies are…
Abstract Number: 1996 • ACR Convergence 2020
Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study
Kevin Winthrop¹, Juan Vargas², Edit Drescher³, Conrado Garcia⁴, Alan Friedman⁵, Jeffrey Enejosa⁵, Nasser Khan⁵, Yihan Li⁵, Justin Klaff⁵ and Alan Kivitz⁶, ¹Oregon Health & Science University, Portland, OR, ²Quantum Research, Puerto Varas, Chile, ³Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁴Hospital General de México "Dr. Eduardo Liceaga", Mexico, Mexico, ⁵AbbVie Inc., North Chicago, IL, ⁶Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA
Background/Purpose: Pneumococcal vaccination is recommended in patients with RA who are receiving conventional synthetic/biologic DMARDs.1 Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to…
Abstract Number: 2043 • ACR Convergence 2020
Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Ravi Kumar¹, Niyaz Yoosuf², Sanjay Boddul², Christina Gerstner³, Sara Turcinov⁴, Anatoly Dubnovitsky⁵, Fredrik Wermeling², Karine Chemin⁶ and Vivianne Malmström⁷, ¹Division of Rheumatology, Department of Medicine, Stickholm, Stockholms Lan, Sweden, ²Division of Rheumatology, Department of Medicine, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, ⁶Division of Rheumatology, Department of Medicine, Stockholm, Stockholms Lan, Sweden, ⁷Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Citrulline (cit) autoimmunity is central in rheumatoid arthritis (RA), including both anti-citrulline protein antibodies (ACPA) and autoreactive CD4+ T cells. While the ACPA are…
Abstract Number: 0044 • ACR Convergence 2020
Characterization of Racial Disparities in Rheumatoid Arthritis Treatment Choice and Location of Care
Elston He¹, Eli Cornblath², Pratyusha Yalamanchi³, Alexis Ogdie², Joshua Baker² and Michael George², ¹Synovium, Inc., Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Michigan Medicine, Ann Arbor, MI
Background/Purpose: Racial disparities in access to care and treatment regimens exist but remain poorly characterized in the rheumatoid arthritis (RA) patient population. Previous studies using…
Abstract Number: 0134 • ACR Convergence 2020
The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial
Sean McKenna¹, Laura Comber², Alan Donnelly³, Alexander Fraser⁴, Bente Appel Esbensen⁵ and Norelee Kennedy³, ¹University of Limerick, Mallow, Cork, Ireland, ²HIQA, Limerick, Limerick, Ireland, ³University of Limerick, Limerick, Limerick, Ireland, ⁴University College Limerick, Limerick, Limerick, Ireland, ⁵University of Copenhagen, Glostrup, Hovedstaden, Denmark
Background/Purpose: Poor sleep quality and reduced sleep duration are prevalent complaints in people with RA. These in turn may further deteriorate functional ability and reduce…
Abstract Number: 0159 • ACR Convergence 2020
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with…
Abstract Number: 0191 • ACR Convergence 2020
Increased Frequency of Lower Limb Arterial Obstruction in Rheumatoid Arthritis
Ahmed Oglah¹, Ali Hussein², Jose Felix Restrepo³, Carlos Lorenzo³, Agustin Escalante³ and Inmaculada Del Rincon³, ¹University of Texas Health Science Center at San Antonio/ Internal Medicine Residency program, San Antonio, TX, ²University of Texas Health Science Center at San Antonio/ Department of Internal Medicine/ Rheumatology, San Antonio, TX, ³University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Despite a high frequency of cardiovascular disease in rheumatoid arthritis (RA), peripheral arterial disease in RA has received little attention. The objective of the…
Abstract Number: 0208 • ACR Convergence 2020
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results
Bernard Combe¹, Alan Kivitz², Yoshiya Tanaka³, Désirée van der Heijde⁴, J-Abraham Simon-Campos⁵, Herbert S. Baraf⁶, Uma Kumar⁷, Franziska Matzkies⁸, Beatrix Bartok⁸, Lei Ye⁸, Ying Guo⁹, Chantal Tasset¹⁰, John S. Sundy⁸, Angelika Jahreis⁸, Neelufar Mozaffarian¹¹, Robert Landewé¹², Sang-Cheol Bae¹³, Edward C Keystone¹⁴ and Peter Nash¹⁵, ¹University of Montpellier, Montpellier, France, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Köhler & Milstein Research, Mérida, Mexico, ⁶The Ctr for Rheumatology and Bone Research, Wheaton, MD, ⁷All India Institute of Medical Sciences, New Delhi, India, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc., Foster City, ¹⁰Galapagos NV, Mechelen, Belgium, ¹¹Ichnos Sciences, Paramus, ¹²Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁴Mount Sinai Hospital, Toronto, ON, Canada, ¹⁵School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 (JAK1) inhibitor. FINCH 1 (NCT02889796) assessed FIL efficacy and safety in patients (pts) with…
Abstract Number: 0225 • ACR Convergence 2020
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
Hawazin Alhazzani¹, Reem Tashkandi¹, Lamia Alzamel¹, Haya Almalag¹, Shiekha Alaujan¹, Abdurhman Alarfaj¹, Hussain Alarfaj¹ and Mohammed Omair¹, ¹King Saud University, Riyadh, Saudi Arabia
Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…
Abstract Number: 0241 • ACR Convergence 2020
A Prospective Analysis of Factors Impacting Medication Adverse Events in Patients with Rheumatoid Arthritis
Elizabeth Salt¹, Amanda Wiggins¹ and Mary Kay Rayens¹, ¹University of Kentucky, Lexington, KY
Background/Purpose: Rheumatoid arthritis (RA), a chronic autoimmune disease affecting approximately 1.5 million people in the U.S., is characterized by inflammation of the synovial tissues with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].